In the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators continually strive to develop therapies that are both highly selective and clinically effective, while addressing targets previously deemed “undruggable”. In recent years, macrocycles – a class of large, ring-shaped molecules – have emerged as a compelling solution at the crossroads between traditional small molecules and large biologics, offering a blend of high specificity, rich chemical diversity and promising pharmacological profiles.
EktaH links novel obesity drug to fat loss, muscle retention in early-phase trial
Latest NewsEktaH has shared early clinical trial data on its first-in-class approach to treating obesity, encouraging the biotech to aim to advance the program into Phase 2 in the first half of next year.
Tolemy Bio raises €1.4m to build AI control panel for cell biology
Latest NewsCambridge-based Tolemy Bio has raised €1.4m in pre-seed financing to develop Orbit, an AI-native platform designed to help biopharma teams interpret, optimise and control cell-based therapeutic processes.
The DASbox® Mini Bioreactor System: Small scale. Big results
ProductsIn the field of bioprocess research and development, precise parameter control and reproducibility are key. Another important factor for economic efficiency of a lab is an effective use of lab space. The DASbox Mini Bioreactor System combines these requirements and more with smart software solutions, parallel bioprocessing option, as well as bioreactor and application flexibility. With this concept, the DASbox Mini Bioreactor System enables you to deliver big results at small scale.
Angelini inks $4.1B Catalyst takeover to fuel US expansion
Latest NewsItaly’s Angelini Pharma has struck a deal to buy Catalyst Pharmaceuticals for $4.1 billion (€3.5 billion) to enter the US market.
InflaRx attracts strong investor interest with US share offering turning to kidney
Latest NewsAs Amgen’s competing therapy has come under growing regulatory scrutiny, an opportunity has emerged for InflaRx N.V. to position its own oral C5aR inhibitor in the market. The Jena-based biotech company is now moving quickly to capitalise on that opening: InflaRx is refocusing its pipeline on severe renal diseases while simultaneously advancing a US$150m capital raise intended to fund development through key clinical milestones.
Scarlet raises £3.2 million to advance lab-grown red blood cell therapies
Latest NewsScarlet Therapeutics has raised £3.2 million (€3.7 million) to take therapies based on red blood cells (RBCs) to in vivo proof of concept, building on evidence that natural and lab-grown cells have comparable half-lives.
For several billions: Bayer adds Perfuse Therapeutics to portfolio of eye therapies
Latest NewsBayer AG is strengthening its ophthalmology portfolio with the acquisition of Perfuse Therapeutics for up to $2.45bn. The focus is on a Phase II candidate for glaucoma and diabetic retinopathy with potential as a disease-modifying therapy.
Switzerland’s biotech sector defies tough markets with record revenue
Latest NewsIf one follows the figures in the Swiss Biotech Report 2026, the green lights are more prominent than the red warning signals. The Swiss biotech industry continued its growth momentum in 2025 and even reached new record highs. According to the industry report presented in early May at Swiss Biotech Day in Basel, total revenue among companies classified as biotech — which in this case explicitly does not include Roche and Novartis, for example — rose to CHF 7.5 billion, up from CHF 7.2 billion the previous year. The drivers were a growing number of market-ready products and persistently strong demand for specialized CDMO services.
Macrocycles: big is the new beautiful
Background, Latest NewsIn the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators continually strive to develop therapies that are both highly selective and clinically effective, while addressing targets previously deemed “undruggable”. In recent years, macrocycles – a class of large, ring-shaped molecules – have emerged as a compelling solution at the crossroads between traditional small molecules and large biologics, offering a blend of high specificity, rich chemical diversity and promising pharmacological profiles.
Swiss Windward Bio adds US$165m to its Chinese pipeline
Latest NewsBasel-based Windward Bio did it again and has raised another three-digit millions – $165 million to be exact – to advance a pipeline of long-acting immunology therapies—much of it sourced through in-licensing deals with Chinese partners. Its lead candidate, WIN378, is moving into Phase III, with first clinical readouts expected from 2026.